Preparation of arsenic trioxide albumim microspheres and its release characteristicsin vitro

Abstract

Arsenic trioxide albumin microspheres (As₂O₃-BSA-NS) were prepared by using methods of chemical cross-linking. The desirability function (DF), calculated according to the size (<1μm) distribution, drug loading and drug trapping efficiency, was introduced as a total index for the microspheres formulation. Four factors, inculding W/O ratio, decentralization speed, BSA concentration and stirring stabilization time, were selected and arranged in an orthogonal experimental table. The release characteristic was studied by the drug release experimentin vitro. The four factors affected DF differently. Decentralization speed behaved as the maximum (P<0.01), followed by BSA concentration (P<0.05) and the W/O ratio dose (P<0.05). Stirring stabilization time did not influence DF (P>0.05). The release experimentin vitro showed that As₂O₃ in As₂O₃-BSA-NS was released more slower than pure As₂O₃. It was concluded that regular As₂O₃-BSA-NS may be prepared by the methods of chemical cross-linking, which was optimized by orthogonal experimental analysis of different factors, and the microspheres can release As₂O₃ slowly.

Keywords

Arsenic trioxide / Albumin microspheres / chemical cross-linking / slow release

References

[1] WangY M, SatoH, AdachiI, et al.. Optimization of formulation design of chitosan microspheres containing cisplatin. J Pharm Sci, 1996, 85(11): 1204-1204

[2] NiuC, YanH, YuT, et al.. Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytics leukemia patients. Blood, 1999, 94: 3315-3315

[3] SoignetS L, MaslakP, WangZ G, et al.. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Eng J Med, 1998, 339: 1341-1341

[4] MaedaH, HoriS, NishitohH, et al.. Tumor growth inhibition by arsenic trioxide (As2O3) in the orthotopic metastasis model of androgen-independent prostate cancer. Cancer Res, 2001, 61(14): 5432-5432

[5] DuY H, HoP C. Arsenic compounds induce cytotoxicity and apoptosis in cisplatin-sensitive and-resistant gynecological cancer cell lines. Cancer Chemother Pharmacol, 2001, 47(6): 481-481

[6] TongQ, ZengF, ZhengL, et al.. Apoptosis inducing effects of arsenic trioxide on human bladder cancer cell line BIU-87. Chin Med J (Engl), 2001, 114(4): 402-402

[7] NakagawaY, AkaoY, MorikawaH, et al.. Arsenic trioxide-induced apoptosis through oxidative stress in cells of colon cancer cell lines. Life Sci, 2002, 70(19): 2253-2253

[8] ChenG C, GuanL S, HuW L, et al.. Functional repression of estrogen receptor α by arsenic trioxide in human breast cancer cells. Anticancer Res, 2002, 22(2A): 633-633

[9] GortziO, PapadimitriouE, KontoyannisC G, et al.. Arsonoliposomes, a novel class of arsenic containing liposomes: effect of palmitoyl-arsonolipid-containing liposomes on the viability of cancer and normal cells in culture. Pharm Res, 2002, 19(1): 79-79

[10] CuvierC, Roblot-TreuplL, ChevillardS, et al.. Doxorubicin loaded nanospheres bypass tumor cell multidrug resistance. Biochem Pharmacol, 1992, 44: 509-509

[11] GortziO, AntimisiarisS G, KlepetsanisP, et al.. Arsonoliposomes: effect of arsonolipid acyl chain length and vesicle composition on their toxicity towards cancer and normal cells in culture. Eur J Pharm Sci, 2003, 18(2): 175-175